Proton pump inhibitors in the management of GERD
- PMID: 19774429
- DOI: 10.1007/s11605-009-1015-3
Proton pump inhibitors in the management of GERD
Abstract
Introduction: Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief.
Results and discussion: Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are "refractory" to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for "failure," is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy.
Conclusion: Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.
Similar articles
-
Lessons learned from intragastric pH monitoring.J Clin Gastroenterol. 2001 Aug;33(2):107-13. doi: 10.1097/00004836-200108000-00003. J Clin Gastroenterol. 2001. PMID: 11468435 Review.
-
Proton pump inhibitors in the management of gastroesophageal reflux disease.Med Arh. 2011;65(1):52-5. Med Arh. 2011. PMID: 21534455 Review.
-
Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo® wireless esophageal pH monitoring study.Rev Gastroenterol Mex. 2017 Oct-Dec;82(4):277-286. doi: 10.1016/j.rgmx.2016.12.007. Epub 2017 Apr 3. Rev Gastroenterol Mex. 2017. PMID: 28385467 English, Spanish.
-
Drugs, bugs, and esophageal pH profiles.Yale J Biol Med. 1999 Mar-Jun;72(2-3):169-72. Yale J Biol Med. 1999. PMID: 10780578 Free PMC article. Review.
-
Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.J Clin Gastroenterol. 2011 Oct;45(9):748-54. doi: 10.1097/MCG.0b013e318224d4ba. J Clin Gastroenterol. 2011. PMID: 21694609 Review.
Cited by
-
Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.Dig Dis Sci. 2019 Mar;64(3):823-831. doi: 10.1007/s10620-018-5377-9. Epub 2018 Nov 21. Dig Dis Sci. 2019. PMID: 30465175 Free PMC article. Clinical Trial.
-
Pathogenesis of pepsin-induced gastroesophageal reflux disease with advanced diagnostic tools and therapeutic implications.Front Med (Lausanne). 2025 Feb 19;12:1516335. doi: 10.3389/fmed.2025.1516335. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40046936 Free PMC article. Review.
-
Salivary pepsin as an independent predictor of treatment response for laryngopharyngeal reflux: prospective cohort study with multivariate analysis.Sci Rep. 2023 Dec 21;13(1):22893. doi: 10.1038/s41598-023-50014-6. Sci Rep. 2023. PMID: 38129481 Free PMC article.
-
Importance of a multidisciplinary approach for the treatment of Barrett's esophagus.Updates Surg. 2011 Mar;63(1):5-9. doi: 10.1007/s13304-011-0049-8. Epub 2011 Feb 10. Updates Surg. 2011. PMID: 21308492 Review.
-
Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?World J Gastroenterol. 2014 Jun 14;20(22):6981-8. doi: 10.3748/wjg.v20.i22.6981. World J Gastroenterol. 2014. PMID: 24944492 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical